Earnings call Sangamo reported significant progress in its Fabry disease program, including positive clinical data and ongoing FDA BLA submission, while raising over $130 million in 2025. However, the ...
Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
ATLANTA, GA, UNITED STATES, January 13, 2026 / EINPresswire.com / — Enlighten Clinical Solutions today announced the official release of its integrated electronic Trial Master File (eTMF) module, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results